Effect of angiotensin-converting enzyme inhibitor (SQ 20881) on the plasma concentration of angiotensin I, angiotensin II, and arginine vasopressin in the dog during hemorrhagic shock.
The effect of an angiotensin-converting enzyme inhibitor on the circulating levels of angiotensin I, angiotensin II, and arginine vasopressin was studied in dogs subjected to hypotensive hemorrhagic shock. In dogs subjected to hemorrhage but not given the inhibitor, angiotensin II rose 20-fold (from 69 to 1,343 pg/ml of plasma), whereas in dogs subjected to hemorrhage but pretreated with the inhibitor, angiotensin II rose only 2-fold (from 92 to 171 pg/ml of plasma). In the pretreated dogs angiotensin I rose 30-fold (from 108 to 3,232 pg/ml of plasma). There was no statistically significant difference between the vasopressin levels found in the untreated dogs and the levels found in dogs given the inhibitor (1,016 and 1,095 pg/ml of plasma). Of the 15 dogs in the untreated group, five died before retransfusion was completed (four of cardiac failure and one of cardiac arrhythmia); none of the 10 dogs in the inhibitor-treated group died. These observations suggest that the very high levels of angiotensin II observed following severe hemorrhage do not contribute significantly to the increased secretion of vasopressin and that the inhibitor protects against death, possibly by suppressing the very high blood levels of angiotensin II observed following this type of experimental hemorrhagic shock.
D000804:Angiotensin II / Q000097:blood*; D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood*; D004285:Dogs; D009842:Oligopeptides / Q000494:pharmacology*; D012771:Shock, Hemorrhagic / Q000097:blood* / Q000188:drug therapy; D013722:Teprotide / Q000494:pharmacology* / Q000627:therapeutic use; D014667:Vasopressins / Q000031:analogs & derivatives*
D009842:Oligopeptides; D014667:Vasopressins; D000804:Angiotensin II; D001127:Arginine Vasopressin; D013722:Teprotide